Clinical study on effect of Shenmai Injection in treating congestive heart failure.
- Author:
Ming-zhi LONG
1
;
Di-bin WANG
;
Ji-ming YANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Biomarkers; Creatine Kinase; blood; Drug Combinations; Drugs, Chinese Herbal; therapeutic use; Female; Heart Failure; blood; drug therapy; Humans; Male; Middle Aged; Panax; Phytotherapy; Schisandraceae; Troponin T; blood
- From: Chinese Journal of Integrated Traditional and Western Medicine 2003;23(11):808-810
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the therapeutic effect of Shenmai Injection (SI) in treating congestive heart failure (CHF).
METHODSThe changes in cAMP, cGMP, serum cardiac troponin T (cTnT, a specific marker reflecting myocardial injury), creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) were simultaneously monitored in 62 chronic CHF patients, distributed in the two groups, the routine treatment group and the routine treatment + SI group, by randomized grouping method, and the therapeutic effect of the two groups was compared.
RESULTSThe plasma cAMP/cGMP ratio increased in early stage and decreased in late stage of the course of CHF. The serum cTnT level was progressively increased along with heart function deterioration. After treated with SI for 2 weeks, the CHF patients' hemodynamics got stable and heart function obviously improved. No serious adverse reaction was found in the therapeutic course.
CONCLUSIONThe level of serum cTnT might be taken as a reliable biochemical parameter to predict the prognosis of CHF patients. SI is an effective and safe agent in treating CHF.
